Outstanding efficacy of Crestor (TM) in treating range of patient populations at risk of CVD

London, UK, 25 October 2004. New data presented today from several studies involving more than 5,000 patients provide further evidence of the outstanding efficacy of CRESTORTM (rosuvastatin) in treating key cardiovascular disease (CVD) risk factors in patients with dyslipidaemia and either atherosclerosis, coronary artery disease, type 2 diabetes or the metabolic syndrome.1-5

Results from five studies (DISCOVERY, COMETS, MERCURY I, URANUS, RADAR) presented at the XV International Symposium on Drugs Affecting Lipid Metabolism (DALM) demonstrate that CRESTOR is superior to atorvastatin in improving lipid profiles associated with an increased cardiovascular risk in a number of patient populations with dyslipidaemia.1-5 Results from MERCURY I and DISCOVERY also show that CRESTOR, at the usual start dose of 10mg, enables more patients achieve their US NCEP ATP III and European LDL-C goals, respectively, compared to atorvastatin 10mg, thereby avoiding the need to titrate to higher doses.1,3

In current clinical practice, LDL-C is the most widely recognised target for lowering patients' cardiovascular risk.6,7 Guideline cholesterol goals are an important tool to assist physicians in the management of cardiovascular disease worldwide. Recently revised evidence-based guidelines set a series of targets for LDL-C reduction, which vary according to the overall risk category of the patient; the higher the patient's risk of cardiovascular events, such as heart attack or stroke, the lower the LDL-C goal.7 However, many patients are not achieving their recommended LDL-C treatment guideline goals, suggesting that more intensive management with effective statin therapy is required.8,9 Results from one study of the global DISCOVERY Programme*, involving 911 'high risk' patients with hypercholesterolaemia, demonstrate that more patients achieve the European LDL-C guideline goal of <3mmol

Contact: Caroline Howe
Shire Health International

Page: 1 2 3

Related medicine news :

1. Outstanding UCLA undergraduates present research
2. Peto and Doll win King Olav Vs Prize for Outstanding Cancer Research
3. Outstanding scholars set to improve geriatric social work in U.S.
4. ZETIA(R) co-administered with fenofibrate provided complementary lipid lowering efficacy
5. Vioxx: An unequal partnership between safety and efficacy
6. Max daily OTC dose of acetaminophen shows efficacy comparable to Rx doses of naproxen for OA pain
7. Seroquel: New data show efficacy and tolerablity in bipolar depression
8. New drug for non-small cell lung cancer shows efficacy
9. Study highlights efficacy of sirolimus stents to prevent restenosis for PTS with CAD
10. Study finds obesity not associated with efficacy of tamoxifen for early-stage breast cancer
11. Landmark antidepressant analysis demonstrated significant efficacy of Effexor®/Effexor XR

Post Your Comments:

(Date:6/19/2019)... ... ... Ovation® Fertility scientists have been invited to present four pieces of research at ... in Vienna, June 23-26, 2019. , Ovation’s oral presentation about the use of artificial ... for Oral Presentation and the Fertility Society of Australia Exchange Award., ...
(Date:6/18/2019)... ... June 18, 2019 , ... Cosmetic Town, an online ... of cosmetic facial rejuvenation in June. The Cosmetic Town website will showcase cosmetic ... performing various methods of cosmetic facial rejuvenation and videos that take viewers behind ...
(Date:6/18/2019)... ... June 18, 2019 , ... NeoTract, a wholly ... field of urology, today announced that Aaron Berger, MD, Associated Urological Specialists, LLC ... designation recognizes that Dr. Aaron Berger has achieved a high level of training ...
(Date:6/16/2019)... NEWPORT BEACH, Calif. (PRWEB) , ... June 14, ... ... Data Protection / Cyber Security solutions, today announced it has received the ... showcasing the award winning DLP that Works Platform along with the latest additions ...
(Date:6/16/2019)... SPRINGFIELD, Mo. (PRWEB) , ... June 15, 2019 , ... ... Convoy of Hope has been committed to helping those in need around the world. ... people in more than 125 countries. Convoy’s work would not be possible without the ...
Breaking Medicine News(10 mins):
(Date:6/24/2019)... ... June 24, 2019 , ... The Conference Forum has announced ... place on September 17-18, 2018 at the Renaissance Waterfront Hotel in Boston, MA, with ... Scott Gottlieb, 23rd Commissioner of the FDA, has chosen DPharm to deliver his perspective ...
(Date:6/24/2019)... ... 24, 2019 , ... Enespro PPE , a manufacturer ... the electrical industry has today announced the release of its guide for companies ... Developing a Culture of Electrical Safety, is written to address the continued challenge ...
(Date:6/20/2019)... ... , ... ERT, a global data and technology company that ... experts will present a series of innovative and educational live sessions and posters ... Diego, June 23-27. , ERT’s industry-recognized thought leaders will share their knowledge on ...
Breaking Medicine Technology:
Cached News: